Source: European Journal of Clinical Pharmacology. Unidades: FM, HU
Subjects: POLIMORFISMO, ANTICOAGULANTES (FARMACOLOGIA), FARMACOGENÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTOS, Paulo Caleb Junior Lima et al. CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation. European Journal of Clinical Pharmacology, v. 69, n. 4, p. 789-797, 2013Tradução . . Disponível em: https://doi.org/10.1007%2Fs00228-012-1404-5. Acesso em: 28 maio 2024.APA
Santos, P. C. J. L., Dinardo, C. L., Schettert, I. T., Soares, R. A. G., Kawabata-Yoshihara, L., Benseñor, I. M., et al. (2013). CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation. European Journal of Clinical Pharmacology, 69( 4), 789-797. doi:10.1007%2Fs00228-012-1404-5NLM
Santos PCJL, Dinardo CL, Schettert IT, Soares RAG, Kawabata-Yoshihara L, Benseñor IM, Krieger JE, Lotufo PA, Pereira AC. CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation [Internet]. European Journal of Clinical Pharmacology. 2013 ; 69( 4): 789-797.[citado 2024 maio 28 ] Available from: https://doi.org/10.1007%2Fs00228-012-1404-5Vancouver
Santos PCJL, Dinardo CL, Schettert IT, Soares RAG, Kawabata-Yoshihara L, Benseñor IM, Krieger JE, Lotufo PA, Pereira AC. CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation [Internet]. European Journal of Clinical Pharmacology. 2013 ; 69( 4): 789-797.[citado 2024 maio 28 ] Available from: https://doi.org/10.1007%2Fs00228-012-1404-5